ArticleTheranostics2020
The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Phosphorylation enhanced OTUD3 deubiquitination ARID3A promotes the progress of cholangiocarcinoma.Oncogene · 2025Article
- Article
- Article
- β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression.Human cell · 2024Article
- Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.Applied biochemistry and biotechnology · 2023Article
- New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis.PeerJ · 2023Review
- Phosphorylation of RXRα mediates the effect of JNK to suppress hepatic FGF21 expression and promote metabolic syndrome.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Article
- The Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Review
- Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Article
- Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells.Frontiers in pharmacology · 2021Article
- Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.Theranostics · 2021Review
- Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma.Theranostics · 2021Article
- Glycogen synthase kinase-3β: a promising candidate in the fight against fibrosis.Theranostics · 2020Review
- LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Shuaishuai ZhangState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Weiwei GaoState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Juan TangState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Huaifang ZhangState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Yuqi ZhouState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Jie LiuState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Kun ChenState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Fangzhou LiuState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Wengang LiThe 174 th Hospital, Xiamen University, Xiang'an, Xiamen 361102, China.
Sally K Y ToSchool of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Alice Sze Tsai WongSchool of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Xiao-Kun ZhangState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Hu ZhouState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
Jin-Zhang ZengState Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an, Xiamen 361102, China.
University of Hong Kong · HK
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularLiver Neoplasms, ExperimentalSorafenibAnimalsAntineoplastic AgentsCell SurvivalGlycogen Synthase Kinase 3 betaHEK293 CellsHep G2 CellsHumansMaleMiceMice, Inbred BALB CNeoplasm TransplantationReceptors, Retinoic AcidRetinoic Acid Receptor alphaAntineoplastic AgentsGlycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseRARA protein, humanReceptors, Retinoic AcidRetinoic Acid Receptor alpharetinoic acid receptor betaRetinoid X Receptor betaSorafenibTretinoinGSK-3βHepatocellular CarcinomaRetinoid ReceptorTarget Therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.